| ||||||||||||||
|
|
|||||||||||||
Department of Anesthesiology and Pain Management, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas
Address correspondence to Paul F. White, PhD, MD, Department of Anesthesiology and Pain Management, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 753909068. Address electronic mail to paul.white{at}utsouthwestern.edu.
| Abstract |
|---|
|
|
|---|
2-agonists) to supplement opioid analgesics. The opioid-sparing effects of these compounds may lead to reduced nausea, vomiting, constipation, urinary retention, respiratory depression and sedation. Therefore, use of non-opioid analgesic techniques can lead to an improved quality of recovery for surgical patients. | Introduction |
|---|
|
|
|---|
Adequacy of postoperative pain control is one of the most important factors in determining when a patient can be safely discharged from a surgical facility and has a major influence on the patients ability to resume their normal activities of daily living (3). Perioperative analgesia has traditionally been provided by opioid analgesics. However, extensive use of opioids is associated with a variety of perioperative side effects, such as ventilatory depression, drowsiness and sedation, postoperative nausea and vomiting (PONV), pruritus, urinary retention, ileus, and constipation, that can delay hospital discharge (4). Intraoperative use of large bolus doses or continuous infusions of potent opioid analgesics may actually increase postoperative pain as a result of their rapid elimination and/or the development of acute tolerance (5). In addition, it has been suggested by the Joint Commission on Accreditation of Healthcare Organizations that excessive use of postoperative opioid analgesics leads to decreased patient satisfaction. Partial opioid agonists (e.g., tramadol) are also associated with increased side effects (e.g., nausea, vomiting, ileus) and patient dissatisfaction compared with both opioid (6) and non-opioid (7,8) analgesics.
Therefore, anesthesiologists and surgeons are increasingly turning to non-opioid analgesic techniques as adjuvants for managing pain during the perioperative period to minimize the adverse effects of analgesic medications. Multimodal or "balanced" analgesic techniques involving the use of smaller doses of opioids in combination with non-opioid analgesic drugs, such as local anesthetics, ketamine, acetaminophen and nonsteroidal antiinflammatory drugs (NSAIDs), are becoming increasingly popular approaches to preventing pain after surgery (Table 1) (911). This review will discuss recent evidence supporting the use of non-opioid analgesic drugs and techniques during the perioperative period for facilitating the recovery process.
|
| Local Anesthetic Techniques |
|---|
|
|
|---|
|
Blockade of the ilioinguinal and iliohypogastric nerves significantly decreases opioid analgesic requirements in both children and adults undergoing inguinal herniorrhaphy by providing 68 h of postoperative pain relief (15,16). Similarly, a subcutaneous ring block of the penis provides effective perioperative analgesia for circumcision (17). Local anesthetic infiltration of the mesosalpinx significantly decreases pain and cramping after laparoscopic tubal ligation (18). Simple instillation of local anesthetic after removal of the gallbladder also reduced right upper quadrant and shoulder pain (10,19). Pain after arthroscopic shoulder surgery was decreased significantly by a suprascapular nerve block (20) and pain after knee surgery was minimized with a femoral nerve block (21). However, more complete perioperative analgesia for painful shoulder and knee procedures requires use of interscalene brachial plexus (22) and combined femoral, obturator, lateral femoral cutaneous, and sciatic nerve (23) blocks, respectively. Although additional preparation time may be required when major peripheral nerve blocks are performed before surgery, these techniques can offer significant advantages compared with general and spinal anesthesia with respect to pain control in the postoperative period (12,13,22,23).
It has been suggested that performing neural blockade with local anesthetics before surgical incision prevents the nociceptive input from altering excitability of the central nervous system by preemptively blocking the N-methyl-d-aspartate- (NMDA) induced "wind up" phenomena and subsequent release of inflammatory mediators (24). The concept of preemptive analgesia, or treating postoperative pain by preventing establishment of central sensitization, seems intuitively logical. However, the clinical relevance of preemptive analgesia has been questioned. Only a small number of well controlled clinical studies have demonstrated any benefit of preincisional versus postincisional analgesic administration (25,26). A quantitative systematic review by Møiniche et al. (27) stated that evidence is still lacking to support the claim that the timing of single-dose or continuous postoperative pain treatment is critically important in the management of postsurgical pain. These investigators concluded that there was no convincing evidence that preemptive treatment with centrally or peripherally administered local anesthetics, NSAIDs, opioid analgesics, or ketamine offers any advantage with respect to postoperative pain relief when compared with a similar analgesic regimen administered after the surgical incision (27). Nevertheless, preincisional local anesthetic administration offers an obvious advantage over infiltration at the end of surgery because it can provide supplemental intraoperative analgesia as well as effective analgesia in the early postoperative period after emergence from anesthesia.
Preincisional infiltration of the surgical wound site with local anesthetics, combined with general anesthesia, is clearly superior to general or spinal anesthesia alone in reducing postoperative pain (28,29). For example, preincisional infiltration of the tonsillar bed with bupivacaine decreased the intensity of both constant pain and pain on swallowing fluids for up to 5 days after tonsillectomy procedures (29). Paracervical block with 0.5% bupivacaine also reduced pain and the need for opioid analgesics after vaginal hysterectomy under general anesthesia (30). Preincisional ilioinguinal-iliohypogastric nerve block not only improves perioperative pain control for inguinal hernia repair but also reduces the need for oral opioid-containing analgesics in the postdischarge period (16). Although local infiltration can reduce incisional pain after laparoscopic cholecystectomy (3134), some investigators have actually reported that infiltration of the trocar sites at the end of surgery provided better pain relief than when the local anesthetic was given before incision (32). The overall analgesic efficacy of trocar wound infiltration after laparoscopic surgery remains controversial (35).
Although preincisional infiltration of the operative site with local anesthetics remains popular for reducing the perioperative opioid analgesic requirement, other simpler local anesthetic delivery systems (e.g., topical applications) have been described (3640). Topical analgesia with a lidocaine aerosol was effective in decreasing pain, as well as the opioid analgesic requirement, after inguinal herniorrhaphy in adults (36), and instillation of 0.25% bupivacaine before surgical closure compared favorably to an ilioinguinal-iliohypogastric nerve block in children undergoing hernia repair (37). Furthermore, the simple application of topical lidocaine jelly or ointment, as well as eutectic mixture of local anesthesia (EMLA) cream, have been shown to be as effective as peripheral nerve blocks or parenteral opioids in providing pain relief after outpatient circumcision (3840). Use of a 5% lidocaine patch has also been reported to be effective in providing peripheral analgesia (41). However, further studies are needed to define the role (if any) of this analgesic device in the postoperative period.
Intracavitary instillation of local anesthetics is another simple, yet effective, technique for providing pain relief during the early postoperative period after laparoscopic and arthroscopic procedures. For example, when 80 mL of lidocaine 0.5% or bupivacaine 0.125% was administered intraperitoneally at the start of the laparoscopic procedure, postoperative scapular pain and the need for opioid analgesic during the first 48 h after surgery were significantly reduced (42). Compared with a control group receiving saline, use of intraperitoneal bupivacaine 0.5% (1530 mL) also led to a larger percentage of patients going home on the day of surgery (79% versus 43%) (43). However, other studies involving intraperitoneal administration of local anesthetics during laparoscopy report inconsistent effects on postoperative pain and the need for opioid analgesics (4454). Some investigators have suggested that the beneficial effects of intraperitoneal bupivacaine are transient and have little impact on patient recovery (49). Furthermore, when bupivacaine was injected at the preperitoneal fascial plane during extraperitoneal laparoscopic hernia repair, it also failed to reduce postoperative pain (55). Subfacial infiltration with bupivacaine 0.5% at the trochar and incision sites reduced pain and the length of stay after laparoscopic nephrectomy procedures (56). Yndgaard et al. (57) demonstrated that subfascially administered lidocaine was significantly more effective than subcutaneous injection in reducing pain after inguinal herniotomy. It is obvious that the location, volume, and timing of the local anesthetic administration are key factors in determining efficacy of intraperitoneal instillation in preventing pain after both superficial and laparoscopic surgery (19,43,53).
Analogous to intraperitoneal administration, intrapleural instillation of local anesthetic solutions has been reported to improve pain control after laparoscopic surgery (5866). Some investigators report that interpleural bupivacaine produced more effective analgesia than intraperitoneal bupivacaine (66) and compared favorably with epidural bupivacaine (58) after laparoscopic cholecystectomy. Compared with standard opioid analgesics, intrapleural bupivacaine achieved better pain relief and greater improvement in postoperative pulmonary function (59,64). In contrast, Oxorn and Whatley (65) reported that postoperative pulmonary mechanics were worsened after intrapleural bupivacaine. Adverse effects on pulmonary function (resulting from muscle weakness) and the risk of systemic local anesthetic toxicity (resulting from rapid systemic absorption) are the major concerns with this technique (66,67). Although intercostal nerve blocks can also improve pain relief after cholecystectomy procedures, this does not necessarily lead to improved pulmonary function (68).
Local anesthetics are also commonly injected into joint spaces to provide analgesia during and after arthroscopic procedures (69,70). In a placebo-controlled study, intraarticular instillation of 30 mL of 0.5% bupivacaine reduced opioid requirements and facilitated early mobilization and discharge after knee arthroscopy (70). In a follow-up study, a combination of intraarticular bupivacaine and systemic ketorolac (60 mg) further decreased pain in the early postoperative recovery period (71). In addition to the local anesthetics, a wide variety of other adjuvants (e.g., morphine, ketorolac, triamcinolone, and clonidine) have also been injected into the intraarticular space to decrease postarthroscopic pain (7277). Small-dose intraarticular morphine, 0.51 mg, combined with bupivacaine, appears to provide the longest-lasting and most cost-effective analgesia after knee arthroscopy (76,77). Although administering intraarticular morphine before knee surgery was reported to provide a longer duration of analgesia and greater opioid-sparing effects than when it was given at the end of surgery (77), the clinical advantage of preemptive intraarticular local anesthetic administration remains controversial (27).
Although local anesthetic supplementation decreases the severity of incisional pain in the early postoperative period, many patients still experience significant pain when the local anesthetic effect wears off. Therefore, continuous (78,79) and/or intermittent perfusion (80,81) of the surgical wound (or peripheral nerve) with local anesthetic solutions has been reintroduced as a way of extending local anesthetic-induced incisional pain relief into the postoperative period. In a study by White et al. (82), infusion of 0.5% bupivacaine (4 mL/h) at the median sternotomy site reduced postoperative pain and opioid analgesic requirement after cardiac surgery. As a result of the opioid-sparing effect, these patients recovered bowel and bladder function more rapidly. Similarly, wound instillation with 0.2% ropivacaine (5 mL/h) improved pain control after spine fusion surgery (83). These continuous local anesthetic infusion techniques can be modified to allow for patient-controlled local anesthetic administration after surgery (84,85).
Investigators have failed to find consistent improvement in pain scores or opioid-sparing effects when the local anesthetic was infused at the incision site after abdominal surgery (57,8688). Efficacy of local anesthetic infusion systems is enhanced when the catheter is placed at the subfacial level or near a peripheral nerve. For example, a continuous popliteal-sciatic nerve block provides improved postoperative analgesia, decreased opioid use, and enhanced patient satisfaction after painful foot and ankle surgery (89,90). Similarly, a continuous infraclavicular brachial plexus block provides highly effective pain control after discharge in patients undergoing shoulder surgery (91). Although continuous local anesthetic infusions with concomitant PCA capability appears to be superior to a continuous infusion alone for prolonging nerve blocks (92,93), many patients elect not to use the PCA function on their electronic pumps (91).
When using a continuous local anesthetic infusion, analgesic efficacy is influenced by a wide variety of factors in addition to location of the catheter system, including the concentration and volume of the local anesthetic solution (82), as well as the accuracy and consistency of the pumps (94). The use of a disposable, nonelectronic infusion system may offer advantages over the electronic pump because its simplicity minimizes the need for troubleshooting (95). However, accuracy of the infusion rate of the nonelectronic pumps can change over time (94). Temperature changes also influence the infusion rate of elastomeric pumps, and battery life is a limiting factor for the electronic pumps (94). With these catheter delivery systems, the risk of infection appears to be small. However, bacterial colonization of the catheter is a common occurrence (96). Patient satisfaction and comfort when using these delivery systems outside the hospital is high, and more than 90% of the patients are comfortable removing the catheter at home (97). Finally, combining local anesthetic infusion techniques with other analgesic modalities as part of multimodal analgesic therapy further improves pain control throughout the perioperative period (98).
Peripheral nerve block techniques are simple, safe, and highly effective approaches to providing perioperative analgesia. Use of long-acting local anesthetics for neural blockade techniques involving the upper (e.g., interscalene brachial plexus block) and lower (e.g., femoral-sciatic nerve block) extremities can facilitate an earlier discharge after major shoulder and knee reconstructive procedures, respectively (99,100). Availability of long-acting local anesthetics that claim less toxicity and greater selectivity with respect to sensory and motor blockade (e.g., ropivacaine) may further enhance the benefits of local anesthetic supplementation after both major and minor surgery.
Although ropivacaine 0.2% provides better pain relief with less motor impairment than lidocaine 1% for continuous interscalene brachial plexus block (101), its clinical advantages relative to equipotent concentrations of bupivacaine are less well established. Addition of adjuvants (e.g., epinephrine, clonidine) that can prolong postoperative analgesia and facilitate recovery when using central and peripheral nerve blocks may be of greater clinical importance (102,103). Interestingly, a more recent study (104) found that clonidines use as an adjunct to ropivacaine as part of a continuous perineural infusion technique failed to reduce postoperative pain and oral analgesic usage or improve the patients quality of sleep after upper extremity surgery when compared with the local anesthetic alone. Although pain control can be improved after orthopedic procedures by continuously infusing local anesthetic solutions (89,90,105107), availability of longer-acting local anesthetic suspensions and "delayed release" formulations containing liposomes or polymer microspheres may minimize the need for continuous infusion catheter delivery systems in the future.
| NSAIDs |
|---|
|
|
|---|
Early reports suggested that parenteral NSAIDs possessed analgesic properties comparable to the traditional opioid analgesics (108110) without opioid-related side effects (111,112). Compared with the partial opioid agonist tramadol, diclofenac produced better postoperative pain relief with fewer side effects after cardiac surgery (8). When administered as an adjuvant during outpatient anesthesia, ketorolac was associated with improved postoperative analgesia and patient comfort compared with fentanyl and the partial opioid agonist, dezocine (112,113). Other investigators reported that ketorolac provided postoperative pain relief similar to that of fentanyl but was associated with less nausea and somnolence, as well as an earlier return of bowel function (114). In most studies, use of ketorolac has been associated with a less frequent incidence of PONV than the opioid analgesics. As a result, patients tolerate oral fluids and are fit for discharge earlier than those receiving only opioid analgesics during the perioperative period. Of interest, ketorolac (30 mg q 6 h) was superior to a dilute local anesthetic infusion (bupivacaine 0.125%) in supplementing epidural PCA hydromorphone in patients undergoing thoracotomy procedures (115). Furthermore, it has been found that the injection of ketorolac (30 mg) at the incision site in combination with local anesthesia resulted in significantly less postoperative pain, a better quality of recovery, and earlier discharge compared with local anesthesia alone (116). In fact, there is evidence for both a peripheral and central analgesic action of NSAIDs (117). However, when ketorolac was substituted for or combined with fentanyl during minor gynecologic and laparoscopic procedures, the beneficial effects of the NSAID were reduced (118,119).
Using shock wave lithotripsy to evaluate the effect of NSAIDs on visceral pain, diclofenac produced only a marginal opioid-sparing effect (120). However, when diclofenac (1 mg/kg IV) was administered before arthroscopic surgery, it was associated with similar pain scores to fentanyl (1 µg/kg IV) (121). Preoperative diclofenac (50 mg) also decreased pain and the opioid analgesic requirements for 24 h after laparoscopic surgery (122). Similarly, preoperative administration of ketorolac to patients undergoing laparoscopic cholecystectomy (119) decreased postoperative opioid requirements and improved some ventilatory variables during the early postoperative period. A perioperative ketorolac infusion (2 mg/h) also improved the quality of postoperative pain relief after abdominal surgery (123). Compared to tramadol (100 mg IV), ketorolac (30 mg IV) produced comparable analgesia with a 68% decreased incidence of PONV after maxillofacial surgery (124). Of interest, diclofenac (1 mg/kg) is alleged to be a more cost-effective alternative to ketorolac (0.5 mg/kg) (125,126).
When diclofenac was administered preoperatively to pediatric patients, the incidence of restlessness and the incidence of crying, as well as the postoperative opioid requirements, were less than in acetaminophen-treated patients (127). Similarly, oral ketorolac (1 mg/kg) was superior to small-dose acetaminophen (10 mg/kg) in children undergoing bilateral myringotomy procedures (128). In children undergoing inguinal hernia repair (129), ketorolac (1 mg/kg IV) compared favorably with caudal bupivacaine 0.2% with respect to pain control and postoperative side effects. In addition, ketorolac-treated children had an improved recovery profile, including less vomiting, shorter times to voiding and ambulation, and earlier discharge home. Intraoperative administration of ketorolac as an adjuvant to general anesthesia in pediatric patients provided postoperative analgesia comparable to morphine with less PONV (130). When ketorolac or morphine is administered for pain control in pediatric patients, ketorolac-induced analgesia developed more slowly but lasted longer (131).
Oral or rectal administration of NSAIDs is also effective and less costly in the prophylactic management of surgical pain (132). For example, when oral naproxen was administered before laparoscopic surgery, postoperative pain scores, opioid requirements, and time to discharge were significantly reduced (133). Furthermore, premedication with oral ibuprofen (800 mg) was associated with superior postoperative analgesia and less nausea compared with fentanyl (75 µg IV) after laparoscopic surgery (134). However, the more important role for oral NSAIDs may be in the postdischarge period. Ibuprofen liquogel (400 mg po) was significantly more effective than celecoxib (200 mg po) in treating pain after oral surgery (135). Ibuprofen (5 mg/kg po) compared favorably to rofecoxib (0.625 mg/kg po) for minimizing postoperative pain when used in combination with acetaminophen (20 mg/kg) before tonsillectomy procedures (136). When used as part of a multimodal analgesic technique consisting of alfentanil, lidocaine, and ketorolac (137), oral ibuprofen (800 mg q 8h) was equianalgesic to paracetamol 800 mg in combination with codeine 60 mg (q 8h) during the first 72 h after discharge, and resulted in better global patient satisfaction and less constipation than opioid-containing oral analgesics. Ibuprofen (400 or 600 mg po) appears to produce comparable analgesia to the combination of tramadol (75112.5 mg) and acetaminophen (650 or 975 mg) for acute postoperative pain relief (138). To achieve the optimal benefit of using NSAIDs in the perioperative period, these compounds should be continued during the postdischarge period as part of a preventative pain management strategy (98).
Despite the obvious benefits of using NSAIDs in the perioperative period, controversy still exists regarding their use because of the potential for gastrointestinal mucosal damage and renal tubular and platelet dysfunction (139). Although some studies have found increased blood loss and risk of reoperation when ketorolac was administered to children undergoing tonsillectomy procedures (140,141), a recent systematic review of the literature suggested that the evidence supporting an increase of bleeding was equivocal at best (142).
| COX-2 Inhibitors |
|---|
|
|
|---|
|
Valdecoxib has been introduced recently for the prevention of postoperative pain, with doses of 2040 mg reducing the opioid requirement by 25%50% after elective surgery (152,153). In patients undergoing oral surgery and bunionectomy, premedication with valdecoxib 40 mg appears to produce the optimal analgesic effect in the postoperative period (152). Valdecoxib is as rapidly acting and effective as oxycodone in combination with acetaminophen but has a longer duration of action and fewer side effects when used for the management of pain after oral surgery. Valdecoxib (40 mg po) was alleged to be even more effective than rofecoxib, 50 mg po, in treating pain after oral surgery (154).
A parenterally active COX-2 inhibitor, parecoxib (a prodrug which is rapidly converted to valdecoxib), has been investigated as an alternative to the parenteral NSAIDs (155157). However, to achieve equi-analgesia with the IV prodrug, a larger dose may be required compared with the orally active drug valdecoxib. Parecoxib is similar pharmacokinetically to both celecoxib and valdecoxib. Preliminary studies suggested that parecoxib (4080 mg IV), was as effective and longer-acting than ketorolac (30 mg IV) in reducing pain after oral (158) and laparotomy surgery (159). Both preoperative and postoperative administration of this COX-2 inhibitor resulted in significant opioid-sparing effects, reduced adverse effects, and improved quality of recovery and patient satisfaction with postoperative pain management (152,160). Unfortunately, one study in patients undergoing cardiac surgery suggested that perioperative use of parecoxib and valdecoxib as part of a 14-day analgesic treatment regimen increased adverse events, including sternal wound infections (161). Another recent study found that although parecoxib, 40 mg IV, was given at induction of anesthesia, it was less effective than ketorolac, 30 mg IV, after tonsillectomy procedures (141). A new more highly-selective COX-2 inhibitor, etoricoxib (120 mg po), provided rapid and long-lasting pain relief after dental surgery (162). A recent study also suggested that etoricoxib was associated with fewer side effects than a standard opioid-containing oral analgesic. Current evidence suggests that the newer COX-2 inhibitors appear to offer minimal advantages over the first-generation COX-2 inhibitors and the nonselective NSAIDs (163,164).
In addition to the growing controversy regarding the potential adverse cardiovascular risks of the COX-2 inhibitors, many orthopedic surgeons are also concerned about the negative influence of these compounds (as well as the traditional NSAIDs) on bone growth (165,166). As COX-2 activity appears to play an important role in bone healing (167169), some orthopedic surgeons have recommended that these drugs be avoided in the early postoperative period (164,165). Because the effect on bone growth is dose-dependent and reversible (166), COX-2 inhibitors should only be used for 35 d in the early postoperative period. Although several review articles on the COX-2 inhibitors have recently been published (163,170172), the question remains as to whether these compounds truly overcome the perceived limitations of the nonselective NSAIDs (173).
| Acetaminophen (Paracetamol) |
|---|
|
|
|---|
An IV formulation of a prodrug of acetaminophen, propacetamol, has been administered to adults as an alternative to ketorolac in the perioperative period (177,178). Propacetamol reduced PCA morphine consumption by 22%46% in patients undergoing major orthopedic surgery (179,180). However, in patients undergoing cardiac surgery, propacetamol (2 g IV every 6 h for 3 d) failed to enhance analgesia, decrease opioid usage, or reduce adverse side effects in the postoperative period (181). Propacetamol has become a popular adjuvant to opioid analgesics for postoperative pain control in Europe; however, this drug may soon be replaced when an investigational IV formulation of acetaminophen becomes available for clinical use (182). Rectal acetaminophen (1.3 g) has also been successfully used as an adjuvant to NSAIDs and local anesthetics as part of a multimodal fast-tracking surgery recovery protocol (183). Given the adverse effects associated with both NSAIDs and COX-2 inhibitors in patients with preexisting cardiovascular disease, acetaminophen may assume a greater role in postoperative pain management in the future (184).
| NMDA Antagonists |
|---|
|
|
|---|
|
Administration of ketamine, 418 µg · kg1 · min1, in combination with propofol, 3090 µg · kg1 · min1, obviated the respiratory depression produced by commonly used sedative-opioid combinations while producing positive mood effects after surgery, and it may even provide for an earlier recovery of cognitive function (186,187). In addition, a single bolus dose of ketamine, 0.10.15 mg/kg IV, during surgery has been reported to produce significant opioid-sparing effects after painful orthopedic and intraabdominal procedures without increasing the incidence of side effects (194200). Ketamine (0.1 mg/kg IM) reduced swallowing-evoked pain after tonsillectomy procedures in children receiving a multimodal analgesic regimen (198). Small doses of epidural ketamine (2030 mg) enhanced epidural morphine-induced analgesia after major upper abdominal surgery (199). Although it was alleged that ketamine possesses preemptive analgesic effects as a result of its ability to inhibit central NMDA receptors (200), well controlled clinical studies have failed to demonstrate significant preemptive analgesic effects (201,202). Interestingly, a modest dose of ketamine (250 µg/kg) after surgery was alleged to improve analgesia in the presence of opioid-resistant pain (203). Acute tolerance to opioid-induced analgesia leading to long-lasting hyperalgesia may be prevented by repeat doses of this NMDA antagonist (204).
Small-doses of the S(+) and R(-) isomers of ketamine have been administered both IV and epidurally in an effort to decrease injury-induced hyperalgesia. Although S(+) ketamine (0.5 mg/kg IV followed by 0.1251 µg/kg/min) failed to improve pain control after arthroscopic knee surgery (205), epidural S(+) ketamine (0.25 mg/kg) enhanced ropivacaine-induced analgesia after total knee arthroplasty (206). Interestingly, transdermal nitroglycerin (5 mg) has been alleged to enhance the spinal analgesia produced by epidural S(+) ketamine (0.10.2 mg/kg) (207). Consistent with an early comparative clinical study involving the ketamine isomers (208). R(-) ketamine (1 mg/kg IV) produced only a short-lasting analgesic effect in the postoperative period (209).
Dextromethorphan, another NMDA receptor antagonist that inhibits wind-up and NMDA-mediated nociceptive responses in dorsal horn neurons, has been alleged to enhance opioid, local anesthetic and NSAID-induced analgesia. Premedication with dextromethorphan (150 mg po) reduced the PCA morphine requirement in the early postoperative period after abdominal hysterectomy procedures but failed to produce prolonged beneficial effects on wound hyperalgesia (210). In patients undergoing laparoscopic cholecystectomy or inguinal herniorrhaphy procedures, dextromethorphan (90 mg po) improved well-being and reduced analgesic consumption, pain intensity and sedation, as well as thermal-induced hyperalgesia (211). Preincisional administration of dextromethorphan, 40120 mg IM, provided some evidence of preemptive analgesia in patients undergoing laparoscopic cholecystectomy and upper abdominal surgery (212,213). Perioperative dextromethorphan (4090 mg IM) reduced the opioid requirement and/or improved pain control after modified radical mastectomy (214). Interestingly, in patients undergoing knee surgery, dextromethorphan (200 mg q 8 h) failed to significantly improve pain management (215). Compared with ibuprofen (400 mg po), dextromethorphan (120 mg po) was significantly less effective in providing postoperative analgesia and was associated with increased nausea in the preoperative period (216). In patients undergoing knee replacement surgery with epidural anesthesia, dextromethorphan (40 mg IM) also failed to produce any preemptive analgesic effect but did enhance pain control in the postoperative period (217).
Other NMDA antagonists are being actively investigated in the perioperative setting. Preoperative amantadine, 200 mg IV, failed to enhance postoperative analgesia in patients undergoing abdominal hysterectomy procedures (218). However, a more recent study reports that perioperative amantadine reduced PCA morphine requirement after radical prostatectomy surgery (219). Further clinical studies are clearly needed to better define the role of noncompetitive NMDA receptor antagonists in the perioperative setting.
| Alpha-2 Adrenergic Agonists |
|---|
|
|
|---|
2-adrenergic agonists, clonidine and dexmedetomidine, produce significant anesthetic and analgesic-sparing effects. Premedication with oral and transdermal clonidine decreased the PCA-morphine requirement 50% after radical prostatectomy surgery (220). Clonidine also improved and prolonged central neuraxis (221,222) and peripheral nerve blocks (223) when administered as part of multimodal analgesic regimens. For example, epidural infusion of clonidine in combination with ropivacaine improved analgesia after major abdominal surgery in children (224). Adding intrathecal clonidine (0.075 mg) to local anesthesia provided excellent analgesia for up to 8 h after urologic surgery (225). Although clonidine, 4 µg/kg IV over 20 min, failed to reduce PCA morphine requirement after lower abdominal surgery in adults, it did reduce pain, nausea, and vomiting while improving patient satisfaction with their pain relief (226). However, when used to treat postoperative pain, clonidine (0.3 mg IV) was apparently ineffective (227).
Dexmedetomidine is a pure
2-agonist that also reduces postoperative pain and opioid analgesic requirement (228). However, its use was associated with increased postoperative sedation and bradycardia. When used for premedication before IV regional anesthesia (229), dexmedetomidine (1 µg/kg IV) reduced patient anxiety, sympathoadrenal responses, and intraoperative opioid analgesic requirement. Compared with propofol (75 µg · kg1 · min1), dexmedetomidine (1 µg/kg followed by 0.40.7 µg · kg1 · h1) had a slower onset and offset of sedation but was associated with improved analgesia and reduced morphine use in the postoperative period (230). Administration of dexmedetomidine, 1 µg/kg followed by 0.4 µg · kg1 · h1, was also associated with a 66% reduction in PCA morphine use in the early postoperative period after major inpatient surgery (231).
| Miscellaneous Non-Opioid Compounds |
|---|
|
|
|---|
Gabapentin (a structural analog of gamma-aminobutyric acid) is an anticonvulsant that has proven useful in the treatment of chronic neuropathic pain and may also be a useful adjuvant in the management of acute postoperative pain (237242). For example, premedication with gabapentin (1.2 g po) reduced postoperative analgesic requirement significantly without increasing side effects (237). When gabapentin (1.2 g) was continued for 10 d after breast surgery (238), it reduced the postoperative opioid analgesic requirement and movement-related pain; however, the overall incidence of chronic pain was unaffected. Recent studies by Dierking et al. (239), Turan et al. (240), and Rorarius et al. (241) suggested that the improvement in postoperative pain control with gabapentin was not necessarily associated with a decrease in opioid-related side effects. Pregabalin, a related compound, has also been reported to possess analgesic potential comparable to that of ibuprofen in treating acute dental pain (242). This review article discussed the potential role of gabapentin and pregabalin in "protective premedication."
Magnesium, a divalent cation, is also alleged to possess antinociceptive effects. For example, Kara et al. (235) reported that perioperative magnesium (30 mg/kg IV followed by an infusion of 0.5 g/h) yielded a significant reduction in the postoperative analgesic requirement after abdominal hysterectomy. A bolus dose of magnesium (50 mg/kg IV) at induction of anesthesia also led to improved pain control and better patient satisfaction with less opioid medication after major orthopedic surgery (243). However, magnesium 50 mg/kg IV failed to produce opioid-sparing effects after open cholecystectomy procedures (244). In addition, a non-opioid multimodal analgesic regimen that included magnesium produced comparable postoperative pain relief with fewer side effects than fentanyl in obese patients undergoing gastric bypass surgery (245). However, other investigators have failed to demonstrate a beneficial effect of magnesium (3050 mg/kg followed by 1015 mg · kg1 · h1) with respect to reducing postoperative pain or the need for opioid analgesics (246). Of interest, intrathecal magnesium was reported to prolong fentanyl analgesia (247).
Neostigmine, a cholinesterase inhibitor, has been reported to possess analgesic properties when doses of 10200 µg were administered in the subarachnoid or epidural spaces (236,248). Although peripherally administered neostigmine failed to produce postoperative analgesia, epidurally administered neostigmine (1 µg/kg) produced more than 5 h of pain relief after knee surgery (249). Neostigmine (10 µg/kg) also enhanced epidural local analgesia (250). Both epidural (60 µg) and spinal (15 µg) neostigmine enhanced morphine-induced neuraxial analgesia (251254). In patients undergoing knee replacement surgery with intrathecal bupivacaine, adjunctive use of neostigmine (50 µg) was alleged to produce better postoperative analgesia than morphine (300 µg) (255). In addition, transdermal nitroglycerin enhanced spinal neostigmine-induced postoperative analgesia without increasing perioperative side effects (256). However, epidural neostigmine (75300 µg) alone produced only modest analgesia after cesarean delivery (257). The primary adverse effects associated with neuraxial neostigmine appear to be mild sedation (257) and PONV (15%30%) (237,253).
Cannabinoids have been reported to reduce hyperalgesia and drug-induced allodynia. However, clinical studies have failed to demonstrate any evidence of postoperative analgesia (258,259). A new antiinflammatory drug, inositol triphosphate, reduced postoperative pain and the need for opioid analgesics after cholecystectomy surgery (260). However, additional well controlled clinical trials are needed with all of these novel adjunctive drugs.
| Nonpharmacologic Techniques |
|---|
|
|
|---|
Clinical studies suggest that electroanalgesia can reduce opioid analgesic requirements up to 60% after surgery (263,264). In addition to reducing pain and the need for oral analgesics, Jensen et al. (265) reported a more rapid recovery of joint mobility after arthroscopic knee surgery. When used as an adjuvant to pharmacologic analgesia, TENS reduced the intensity of exercise-induced pain and facilitated ambulation after abdominal surgery (266). In reviewing the medical literature, Carroll et al. (267) found conflicting results regarding the effect of TENS on the requirement for opioid analgesic medication and the quality of postoperative pain relief. Studies suggest that the location, intensity, timing, and frequency of electrical stimulation are all important variables influencing the efficacy of electroanalgesics therapies (263,264,268). More recent studies have confirmed the importance of these variables in achieving improved pain relief with TENS therapy (269).
Of interest, simple (mechanical) intradermal needles placed in the paravertebral region before abdominal surgery reduced postoperative pain and the opioid analgesic requirement as well as PONV (270). However, a "minute sphere"-induced acupressure technique (in which 1-mm stainless steel spheres are applied at known analgesic acupoints) failed to relieve pain after major abdominal surgery (271). Other nonpharmacologic approaches that have been used as analgesic adjuvants in the perioperative period include cryoanalgesia (272), ultrasound (273), and laser stimulation (274), as well as hypnotherapy. However, well controlled clinical studies are needed to establish benefits of these nonpharmacologic modalities on postoperative pain and patient outcomes after surgery.
| Summary |
|---|
|
|
|---|
Opioid analgesics continue to play an important role in the management of moderate-to-severe pain after surgical procedures. However, adjunctive use of non-opioid analgesics will likely assume a greater role as minimally invasive ("key hole") surgery continues to expand (2,4). In addition to the local anesthetics, NSAIDs, COX-2 inhibitors, acetaminophen, ketamine, dextromethorphan,
-2 agonists, gabapentin, magnesium, and neostigmine may all prove to be useful adjuncts in the management of postoperative pain in the future. Adjunctive use of droperidol (234) and glucocorticoid steroids (277,278) also appear to provide beneficial effects in the postoperative period. Use of analgesic drug combinations with differing mechanisms of action as part of a multimodal regimen will provide additive (or even synergistic) effects with respect to improving pain control, reducing the need for opioid analgesics, and facilitating the recovery process (279). Safer, simpler, and less costly analgesic drug delivery systems are needed to provide cost-effective pain relief in the postdischarge period as more major surgery is performed on an ambulatory (or short-stay) basis in the future. In introducing new therapeutic modalities for pain management, it is important to carefully consider the risk:benefit ratio (280).
In conclusion, the optimal non-opioid analgesic technique for postoperative pain management would not only reduce pain scores and enhance patient satisfaction but also facilitate earlier mobilization and rehabilitation by reducing pain-related complications after surgery. Recent evidence suggests that this goal can be best achieved by using a combination of preemptive techniques involving both central and peripheral-acting analgesic drugs and devices.
| Footnotes |
|---|
Accepted for publication June 22, 2005.
| References |
|---|
|
|
|---|